Minireviews
Copyright ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Stem Cells. Feb 26, 2021; 13(2): 155-167
Published online Feb 26, 2021. doi: 10.4252/wjsc.v13.i2.155
Platelet-rich plasma vs bone marrow aspirate concentrate: An overview of mechanisms of action and orthobiologic synergistic effects
José Fábio Santos Duarte Lana, Lucas Furtado da Fonseca, Rafael da Rocha Macedo, Tomas Mosaner, William Murrell, Ashok Kumar, Joseph Purita, Marco Antonio Percope de Andrade
José Fábio Santos Duarte Lana, Tomas Mosaner, Department of Orthopedics, The Bone and Cartilage Institute, Indaiatuba 13334-170, SP, Brazil
Lucas Furtado da Fonseca, Department of Orthopedics, The Federal University of São Paulo, São Paulo 04023-062, SP, Brazil
Rafael da Rocha Macedo, Department of Orthopedics, Rede D’Or Unit IFOR Hospital, São Bernardo do Campo 09715-021, SP, Brazil
William Murrell, Department of Orthopaedics, Healthpoint UAE, Abu Dhabi 00000, United Arab Emirates
Ashok Kumar, Department of Orthopaedics, My Doc Specialist Medical Centre, Dubai 00000, United Arab Emirates
Joseph Purita, Department of Orthopedics, Institute of Regenerative Medicine, Boca Raton, FL 33432, United States
Marco Antonio Percope de Andrade, Department of Orthopaedic, Federal University of Minas Gerais, Belo Horizonte 31270-901, MG, Brazil
Author contributions: Purita J wrote the manuscript; de Andrade MAP proposed the research subtopics; Kumar A was responsible for navigating the literature and sharing the relevant studies that were included in this review; Murrell W and da Fonseca LF shared significant knowledge regarding the use of orthobiologics in regenerative medicine; Mosaner T formatted the citations and compiled the references; Macedo RR revised and formatted the body of the manuscript and verified spelling, punctuation and grammatical errors; Lana JFSD was responsible for reviewing and approving all the modifications made to the manuscript from draft to final version.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: José Fábio Santos Duarte Lana, MD, Chief Doctor, Surgeon, Department of Orthopedics, The Bone and Cartilage Institute, 1386 Presidente Kennedy Avenue, Indaiatuba 13334-170, SP, Brazil. josefabiolana@gmail.com
Received: September 26, 2020
Peer-review started: September 26, 2020
First decision: November 3, 2020
Revised: December 15, 2020
Accepted: January 15, 2021
Article in press: January 15, 2021
Published online: February 26, 2021
Processing time: 151 Days and 0.3 Hours
Abstract

The use of orthobiologics as a novel therapy for the treatment of numerous musculoskeletal disorders has increased considerably over the past decade. Currently, there are multiple alternatives available as suitable treatments; however, the use of autologous blood-derived products such as platelet-rich plasma (PRP), bone marrow aspirate (BMA) and BMA concentrate (BMAC), specifically, is expanding. Although many investigations attempted to demonstrate the effectiveness of these therapies, even with positive results, the literature lacks standardized protocols and overall accuracy in study designs, which leads to variance and difficulty in reproducibility of protocols. The efficacy of PRP for the treatment of cartilage, bone and muscle tissues is well known. Although BMAC has generated optimistic results for the same purposes, its applicability in clinical trials is still relatively recent when compared to PRP. Both products demonstrate the potential to set forth reparative processes, each in their own distinct mechanism. The combination of these biological products has been previously proposed, yet little is known about their synergism. Evidence indicates that growth factor, cytokine, and chemokine profiles seen in both PRP and BMAC vary but are likely to work synergistically to enhance musculoskeletal healing. BMAC products seem to work well without PRP; however, the addition of PRP to BMAC has been shown to act as a rich and natural source of culture medium for stem cells located either peripherally or in the bone marrow itself. Nevertheless, additional variables associated with the use of BMAC and PRP in orthopedics must be further evaluated in order to consolidate the efficacy of this therapeutic strategy.

Keywords: Orthobiologics; Platelet-rich plasma; Bone-marrow aspirate; Regenerative medicine; Musculoskeletal diseases; Stem cells

Core Tip: Degenerative musculoskeletal disorders are one of the top causes of pain and disability in the adult population. The use of certain analgesics delivers short term results but do not address the etiological source of pain and disability. The demand for musculoskeletal tissue regeneration has led to an alternative approach referred to as orthobiologics, which is based on cellular and molecular components capable of promoting tissue repair. Platelet-rich plasma and bone marrow aspirate concentrate are popular orthobiologic products that may work synergistically in order to enhance the treatment of musculoskeletal conditions.